Midazolam
FDA-approved product (spray, nasal), marketed as Midazolam In 0.8% Sodium Chloride, Midazolam In 0.9% Sodium Chloride, Nayzilam and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Amnesia
- Epilepsy
- Seizure
- Status epilepticus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Benzodiazepine derivatives
- FDA pharmacologic class
- Benzodiazepine FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Midazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.9% AI-predicted activityagainst E. coli27 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Analgesic Effects of Midazolam in Human Volunteers
NCT02629146 · start 2015-12
Registered record
- Registry ID
- NCT02629146
- Conditions
- Analgesic Drugs; Antinociceptive Agents
- Interventions
- Midazolam; Fentanyl; Isotonic saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-12
- Completion
- 2016-03
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnalgesic Drugs; Antinociceptive AgentsInterventionMidazolam; Fentanyl; Isotonic salinePhasePhase 4Registry statusCompletedOpen Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT02647086 · start 2015-12
Registered record
- Registry ID
- NCT02647086
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab; Midazolam; Omeprazole; Warfarin; Caffeine; Metoprolol
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-12
- Completion
- 2016-07
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtopic DermatitisInterventionDupilumab; Midazolam; Omeprazole; Warfarin +2 morePhasePhase 1Registry statusCompletedDabigatran in an Interaction Probe Drug Cocktail
NCT02361619 · start 2015-02
Registered record
- Registry ID
- NCT02361619
- Conditions
- Healthy Volunteers
- Interventions
- Caffeine; Diclofenac; Esomeprazole; Metoprolol; Midazolam; Dabigatran; Clarithromycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-02
- Completion
- 2017-06
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionCaffeine; Diclofenac; Esomeprazole; Metoprolol +3 morePhasePhase 1Registry statusCompletedPilot Study on Pairing Sedation Strategies and Weaning
NCT02219659 · start 2014-12
Registered record
- Registry ID
- NCT02219659
- Conditions
- Acute Respiratory Failure
- Interventions
- Sedation Protocol with Daily Interruption; Sedation Protocol Without Daily Interruption; Fentanyl Push First
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2018-05-18
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Respiratory FailureInterventionSedation Protocol with Daily Interruption; Sedation Protocol Without Daily Interruption; Fentanyl Push FirstPhaseNot applicableRegistry statusCompletedEfficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration
NCT02396537 · start 2014-01
Registered record
- Registry ID
- NCT02396537
- Conditions
- Pain
- Interventions
- Lidocaine; Midazolam; 0.9% Saline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-01
- Completion
- 2014-08
- Enrolment
- 77
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionLidocaine; Midazolam; 0.9% SalinePhaseNot applicableRegistry statusCompletedPatient Satisfaction With Propofol for Out Patient Colonoscopy
NCT02937506 · start 2013-11
Registered record
- Registry ID
- NCT02937506
- Conditions
- Colon Cancer; IBS; Polyps
- Interventions
- Propofol; Fentanyl Plus Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-11
- Completion
- 2016-08
- Enrolment
- 600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColon Cancer; IBS; PolypsInterventionPropofol; Fentanyl Plus MidazolamPhasePhase 4Registry statusCompletedEffects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children
NCT02013986 · start 2013-09
Registered record
- Registry ID
- NCT02013986
- Conditions
- Congenital Hydronephrosis; Congenital Choledochal Cyst; Fracture
- Interventions
- etomidate; midazolam; propofol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2013-09
- Completion
- 2014-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCongenital Hydronephrosis; Congenital Choledochal Cyst; FractureInterventionetomidate; midazolam; propofolPhasePhase 4Registry statusUnknownSevoflurane- Safety in Long-term Sedation Procedures
NCT01802255 · start 2013-03
Registered record
- Registry ID
- NCT01802255
- Conditions
- Poisoning by Inhaled Anaesthetic; Fluoride Poisoning; Recovery From Sedation; Renal Function; Hepatic Function
- Interventions
- Sevoflurane; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2013-03
- Completion
- 2015-06
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPoisoning by Inhaled Anaesthetic; Fluoride Poisoning; Recovery From Sedation; Renal Function +1 moreInterventionSevoflurane; MidazolamPhasePhase 3Registry statusWithdrawnPerformance of Endoscopic Submucosal Dissection According to the Sedation Method
NCT01806753 · start 2013-03
Registered record
- Registry ID
- NCT01806753
- Conditions
- Early Gastric Cancer; Gastric Adenoma
- Interventions
- Intermittent midazolam/propofol injection controlled by endoscopist; Continuous propofol infusion with opioid administration
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2014-01
- Enrolment
- 157
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEarly Gastric Cancer; Gastric AdenomaInterventionIntermittent midazolam/propofol injection controlled by endoscopist; Continuous propofol infusion with opioid administrationPhaseNot applicableRegistry statusCompletedStudy to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
NCT01529034 · start 2012-07
Registered record
- Registry ID
- NCT01529034
- Conditions
- Epilepsy
- Interventions
- USL261
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2012-07
- Completion
- Not recorded
- Enrolment
- 175
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsyInterventionUSL261PhasePhase 3Registry statusTerminatedDexmedetomidine Premedication in Hypertensive Patients
NCT02058485 · start 2012-01
Registered record
- Registry ID
- NCT02058485
- Conditions
- Hypertension
- Interventions
- Midazolam; Dexmedetomidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2013-06
- Enrolment
- 162
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionMidazolam; DexmedetomidinePhasePhase 3Registry statusCompletedSafety Evaluation of Dexmedetomidine for EBUS-TBNA
NCT01381627 · start 2011-06
Registered record
- Registry ID
- NCT01381627
- Conditions
- Lung Cancer
- Interventions
- Remifentanil; Dexmedetomidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2011-06
- Completion
- 2013-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung CancerInterventionRemifentanil; DexmedetomidinePhasePhase 4Registry statusUnknownStudy of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia
NCT02136641 · start 2011-06
Registered record
- Registry ID
- NCT02136641
- Conditions
- Anesthesia; Reaction
- Interventions
- Midazolam; Midazolam+Fentanyl Combination; Midazolam+Ketamine Combination
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2012-06
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnesthesia; ReactionInterventionMidazolam; Midazolam+Fentanyl Combination; Midazolam+Ketamine CombinationPhasePhase 4Registry statusCompletedThe Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
NCT01221727 · start 2010-11
Registered record
- Registry ID
- NCT01221727
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Denosumab; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2011-07
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopausal OsteoporosisInterventionDenosumab; MidazolamPhasePhase 1Registry statusCompletedPharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
NCT01162486 · start 2010-04
Registered record
- Registry ID
- NCT01162486
- Conditions
- Tuberculosis; Tuberculosis, Pulmonary
- Interventions
- Rifampin & midazolam; rifapentine & midazolam; rifapentine & midazolam; rifapentine & midazolam; rifapentine and midazolam; rifapentine and midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-03
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis; Tuberculosis, PulmonaryInterventionRifampin & midazolam; rifapentine & midazolam; rifapentine & midazolam; rifapentine & midazolam +2 morePhasePhase 1Registry statusCompleted